Asher Biotherapeutics is pioneering cis-targeted immunotherapies that selectively activate immune cell types to enhance therapeutic efficacy while minimizing side effects
Asher Biotherapeutics is pioneering cis-targeted immunotherapies that selectively activate immune cell types to enhance therapeutic efficacy while minimizing side effects. Their lead product, etakafusp alfa, is designed for the treatment of solid tumors.